QIAGEN and Pathway Diagnostics Sign Agreement to Address Biomarker Development Needs in Pharma
QIAGEN N.V. and Pathway Diagnostics Corporation announced a co-marketing partnership. The new partnership shall allow customers in the biotechnology and pharmaceutical industries to leverage QIAGEN's sample and assay technology platforms in combination with Pathway Diagnostics' clinical development and testing service capabilities. Under the partnership, QIAGEN's global pharmaceutical sales channel and resource network shall develop project opportunities which can be addressed together with the service capabilities of Pathway Diagnostics.
Most read news
Other news from the department business & finance

Get the analytics and lab tech industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.